Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
35 36 Next >
News headline image
3 Unstoppable Stocks to Buy Hand Over Fist in April ↗
These stocks have exceptionally bright prospects. 
Via The Motley Fool
News headline image
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why ↗
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition ↗
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine. 
Via InvestorPlace
News headline image
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000 ↗
Each of these three companies are entering a new era of growth. 
Via The Motley Fool
News headline image
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move ↗
The price could be right for these three biopharma stocks. 
Via The Motley Fool
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today ↗
 
Via Benzinga
News headline image
Is It Too Late to Buy CRISPR Therapeutics Stock? ↗
The biotech has been making a lot of noise since late last year. 
Via The Motley Fool
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗
 
Via Benzinga
News headline image
3 Stocks That Could Be the Next Big Thing in Gene Editing ↗
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
News headline image
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
News headline image
The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024 ↗
These undervalued Cathie Wood stocks capture her favorite trends and remain undervalued even as the wider tech sector surge. 
Via InvestorPlace
News headline image
7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
News headline image
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz ↗
On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new 
Via Benzinga
News headline image
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility ↗
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
News headline image
The Top 3 Biotech Stocks to Buy in March 2024 ↗
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors. 
Via InvestorPlace
News headline image
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
News headline image
Here's Why CRISPR Therapeutics Stock Climbed 34% in February ↗
The biotech company keeps moving closer to bringing its promising first gene therapy to market. 
Via The Motley Fool
News headline image
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential ↗
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
News headline image
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst ↗
This company's fortunes are likely to improve, and soon. 
Via The Motley Fool
News headline image
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now ↗
The futures for these two beaten-down stocks could be brighter than their recent pasts. 
Via The Motley Fool
News headline image
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks Bound to Blast Off By 2029 ↗
Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years. 
Via InvestorPlace
News headline image
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
News headline image
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗
Vertex shares have climbed almost 50% over the past year. 
Via The Motley Fool
News headline image
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy and Hold for the Next 10 Years ↗
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗
Buy this stock if you're daring, but avoid it for now if you aren't. 
Via The Motley Fool
News headline image
Three S&P 500 Giants Lead This List Of Stocks Near Buy Points ↗
Watch these five stocks, but the market is slightly extended. 
Via Investor's Business Daily
Topics Stocks
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.